Meningococcal B vaccine shows promise

The bivalent vaccine, designed to protect against the serotype causing the most disease in Australia, New Zealand, Europe and North America, was generally well-tolerated, lead author Professor Peter Richmond, from the Telethon Institute for Child Health, said.

“If additional studies show similar immunogenicity and tolerability, this vaccine might help to reduce the global burden of invasive meningococcal disease,” he said.

The development of a protective vaccine against the diverse serogroup B strains has been challenging due to protein surface variations on the bacteria, the researchers said in a